tbuckley/cabot-search huggingface dataset:
Reversible neutropenia from vancomycin
Authors: C. D. Borland
Journal: JAMA (1979)

<h3>To the Editor.—</h3> Although ototoxicity and nephrotoxicity are the most feared complications associated with vancomycin hydrochloride,<sup>1</sup>at least seven patients in whom neutropenia developed have been described in the literature (236:1604, 1976).<sup>2-4</sup>Three additional cases have been reported to the Eli Lilly Company (Dr A. F. Crumley, written communication, Penicillin Gand Gentamicin Sulfate Erythromycin and Rifampin 20,000 — 10,000 — Vancomycin Hydrochloride Total WBC Count —Neutrophil Count 10 20 30 40 50 Day of Hospitalization 60 70 80 90 Total WBC and neutrophil counts during hospitalization. 1978). In most of the well-documented cases, the patient was receiving or had recently received other agents that might have caused the neutropenia. We have recently seen a patient whose severe
Promotion of Women Physicians in Academic Medicine
Authors: Carole J. Bland
Journal: JAMA (1995)

<h3>To the Editor.</h3> —In the article on gender differences in promotion, Dr Tesch and colleagues<sup>1</sup>state that there was no evidence that women had less academic preparation. We wonder if the assessment of academic preparation was too superficial to detect differences in preparation. For example, a study of graduates of family medicine fellowships found six variables that discriminated between graduates who published and those who did not. The six predictive variables were, in rank order, program affiliation (institution), training emphasis in fellowship on how data should be analyzed, time spent in research, encouragement to attend regional and national meetings (networking), current position (tenured vs nontenured), influence over own activities, and organization.<sup>2</sup>In the study by Tesch et al, given that sufficient detail to detect differences in preparation may not have been gathered, perhaps the true measure of the effectiveness of fellowship training and socialization were the significant differences
Elevated plasma levels of pentraxin 3 in patients with chronic heart failure Marco Metra, Massimo Locati, Giuseppe Peri, Savina Nodari, Federica Vigliani, A. Doni, Alberto Mantovani, Livio Dei Cas. Chair of Cardiology, Brescia, Italy, Department of Biotechnology, Section of General Pathology, Brescia, Italy
Journal: Journal of the American College of Cardiology (2001)
Obstetric complications as risk factors for cerebral palsy or seizure disorders
Authors: K. B. Nelson
Journal: JAMA (1984)

In a prospective study, late obstetric complications were common, one or more occurring in 62% of 51,285 pregnancies. We examined these complications as risk factors for cerebral palsy (CP) or nonfebrile seizure disorders. Certain complications were associated with an increased rate of CP, but in babies over 2,500 g, the observed rate of CP did not exceed 2% following any condition evaluated. For most conditions, the CP rate was highest in the small subgroup of children who had five-minute Apgar scores of 3 or less. Most babies over 2,500 g born after each complication achieved five-minute Apgar scores of 7 or higher, and for them the risk of CP was not significantly greater than in children whose births were uncomplicated. Neither the complications considered nor Apgar scores were important antecedents of nonfebrile seizure disorders in children free of CP. (<i>JAMA</i>1984;251:1843-1848)
Medical and Biological Illustration, London
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Leads from the MMWR. Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infections
Journal: JAMA (1986)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Years of Potential Life Lost Before Age 65—United States, 1987
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Physical Training
Authors: D. P. Gurd
Journal: BMJ (1935)

<h3>Background</h3> In the past two decades, health inequality has persisted or increased in states with comprehensive welfare. <h3>Methods</h3> We conducted a national registry-based repeated cohort study with a 3-year follow-up between 1990 and 2007 in Sweden. Information on all-cause mortality in all working-age Swedish men and women aged between 30 and 64 years was collected. Data were subjected to temporal trend analysis using joinpoint regression to statistically confirm the trajectories observed. <h3>Results</h3> Among men, age-standardised mortality rate decreased by 38.3% from 234.9 to 145 (per 100 000 population) over the whole period in the highest income quintile, whereas the reduction was only 18.3% (from 774.5 to 632.5) in the lowest quintile. Among women, mortality decreased by 40% (from 187.4 to 112.5) in the highest income group, but increased by 12.1% (from 280.2 to 314.2) in the poorest income group. Joinpoint regression identified that the differences in age-standardised mortality between the highest and the lowest income quintiles decreased among men by 18.85 annually between 1990 and 1994 (p trend=0.02), whereas it increased later, with a 2.88 point increase per year (p trend &lt;0.0001). Among women, it continuously increased by 9.26/year (p trend &lt;0.0001). In relative terms, age-adjusted mortality rate ratios showed a continuous increase in both genders. <h3>Conclusions</h3> Income-based inequalities among working-age male and female Swedes have increased since the late 1990s, whereas in absolute terms the increase was less remarkable among men. Structural and behavioural factors explaining this trend, such as the economic recession in the early 1990s, should be studied further.
The Changing Role of Animal Toxicology in Support of Regulatory Decisions
Authors: Frederick J. Miller, Judith A. Graham, Donald E. Gardner
Journal: Environmental Health Perspectives (1983)

The Clean Air Act is the basic U.S. Federal law for controlling air pollution. Under Sections 108 and 109, primary (health) national ambient air quality standards (NAAQS) can be set for pollutants which are ubiquitous in the ambient air. The standard-setting process includes a comprehensive summary of scientific information on effects and controls in criteria and control techniques, and the selection of an appropriate standard which, in the judgment of the Administrator, protects the health of normal and susceptible subpopulations with an adequate margin of safety. Determining the adequacy of existing NAAQS or establishing new standards requires that the scientific information base be evaluated to assess pollutant effects on public health. Improvements in this process can be accomplished not only through new health effects research, but also through improved use of currently available data. The commonality joining these two efforts is in the area of extrapolation modeling, which is the topic of this paper. Extrapolation modeling involves determining the effective dose delivered to the target organ of several species and the sensitivity of the target organ to that dose so that effective pollutant concentrations can be estimated across species. This in turn allows greater utilization of the results from animals in making judgments about the effects in man from exposure to a given pollutant.
TRAINING NURSES BY MAIL.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
EFFICIENCY IN HEALTH ADMINISTRATION.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
NO FULL DRESS UNIFORM.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 2185: Efficacy of Rac/Cdc42 inhibitors in multiple cancer models
Authors: Jean F. Ruiz Calderon, Linette Castillo-Pichardo, Irmaris Lopez-Lopez, Suranganie Dharmawardhane
Journal: Cancer Research (2019)

Abstract The RhoGTPases Rac and Cdc42 are excellent therapeutic targets for inhibiting metastasis because these homologous proteins regulate numerous cellular functions that promote tumorigenesis, angiogenesis, invasion and therefore, metastasis. Also, Rac1, Cdc42, and their effector p21-activated kinase (PAK) are overexpressed in multiple cancer types, including breast, gastric, and pancreatic, and are associated with higher mortality rates. Furthermore, Rac and Cdc42 are activated through the signaling of oncogenic cell surface receptors such as EGFR and HER2, therefore hyperactivating their signaling pathways. Our laboratory has developed two small molecules targeting Rac and Cdc42, Ehop-016 and MBQ-167, that inhibit Rac1 and Cdc42 with IC50s in the low micro- and nano-molar concentrations, respectively (Montalvo-Ortiz et al. 2012, J Biol Chem; Humphries-Bickley et al. 2017, Mol Cancer Therap), making them the most potent Rac/Cdc42 inhibitors developed to date. We hypothesize that targeting Rac1, 3, and Cdc42 is a rational strategy to inhibit aggressive TNBC, pancreatic and gastric cancer. To test this hypothesis, we treated the TNBC cell lines MDA-MB-231, MDA-MB-468 and 4T1 (murine breast cancer), gastric cancer cells NCI-N87, and pancreatic cancer cells MIA-PaCa-2 with 4uM and 500nM of Ehop-016 and MBQ-167 respectively, and measured cell viability. Both TNBC cell lines and the pancreatic cancer cell line exhibited a drastic reduction in cell viability (&amp;gt60%) after 48hrs of treatment Ehop-016 or MBQ-167. Additionally, experimental and spontaneous metastasis assays were performed with TNBC and gastric cancer xenografts in immunocompromised and immunocompetent mice. Treatment with 1 mg/kg BW MBQ-167 3X week resulted in reduced tumor growth by 60-90% in TNBC and gastric cancer models, and metastasis inhibition by ~90% in the MDA-MB-231 model. In the syngeneic experimental metastasis study with 4T1, both Ehop-016 and MBQ-167 reduced lung metastasis in comparison to the vehicle treated group. Moreover, these compounds were not toxic to both immunocompromised and immunocompetent mice, as observed by no significant changes in weight and liver enzymes. Therefore, both Ehop-016 and MBQ-167 are promising targeted therapeutics against cancers that overexpress Rac, Cdc42, and PAK. Citation Format: Jean F. Ruiz Calderon, Linette Castillo-Pichardo, Irmaris Lopez-Lopez, Suranganie Dharmawardhane. Efficacy of Rac/Cdc42 inhibitors in multiple cancer models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2185.
MEDICAL SCHOOLS OF LOW STANDARDS.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
US Preventive Services Task Force. Sigmoidoscopy in the periodic health examination of asymptomatic adults
Authors: J. V. Selby
Journal: JAMA (1989)

PERIODIC screening sigmoidoscopic examination of asymptomatic persons has been recommended for more than 30 years<sup>1-3</sup>as a means of reducing mortality from colorectal cancer. However, evidence supporting this recommendation is limited and expert opinion, as reflected in several recent reviews,<sup>4-8</sup>differs as to whether sigmoidoscopy should be included in the periodic health examination. Colorectal cancer, with a cumulative incidence of 5.1% in men and 3.9% in women by age 74 years,<sup>9</sup>is the second leading cause of cancer mortality in the United States. More than 145 000 new cases and 61000 deaths from this disease are expected for 1987.<sup>10</sup>Thus, screening tests that can lead to earlier detection and improved survival are needed. In addition to earlier detection, screening sigmoidoscopy may reduce the incidence of colorectal cancer through removal of premalignant adenomatous polyps. In evaluating sigmoidoscopy as a screening test, it is important to distinguish between
International Congress of Psychotherapy Internationaler Kongress für Psychotherapie Congrès International de Psychotherapie
Authors: Stjepan Betlheim, Duška Blažević, Oluf Brüel, R. Brun, A. Caruso, E.E. Krapf, A. Maeder, Berthold Stokvis, Erwin Stransky, M. Boss
Journal: Psychotherapy and Psychosomatics (1955)
Longitudinal Investigation of Exposure to Arsenic, Cadmium, and Lead in Drinking Water
Authors: P. Barry Ryan, Natalie Huet, David L. MacIntosh
Journal: Environmental Health Perspectives (2000)

Arsenic, cadmium, and lead have been associated with various forms of cancer, nephrotoxicity, central nervous system effects, and cardiovascular disease in humans. Drinking water is a well-recognized pathway of exposure to these metals. To improve understanding of the temporal dimension of exposure to As, Cd, and Pb in drinking water, we obtained 381 samples of tap and/or tap/filtered water and self-reported rates of drinking water consumption from 73 members of a stratified random sample in Maryland. Data were collected at approximately 2-month intervals from September 1995 through September 1996. Concentrations of As (range < 0.2-13.8 microg/L) and Pb (< 0.1-13.4 microg/L) were within the ranges reported for the United States, as were the rates of drinking water consumption (median < 0.1-4.1 L/day). Cd was present at a detectable level in only 8.1% of the water samples. Mean log-transformed concentrations and exposures for As and Pb varied significantly among sampling cycles and among respondents, as did rates of drinking water consumption, according to a generalized linear model that accounted for potential correlation among repeated measures from the same respondent. We used the intraclass correlation coefficient of reliability to attribute the total variance observed for each exposure metric to between-person and within-person variability. Between-person variability was estimated to account for 67, 81, and 55% of the total variance in drinking water consumption, As exposure (micrograms per day), and Pb exposure (micrograms per day), respectively. We discuss these results with respect to their implications for future exposure assessment research, quantitative risk assessment, and environmental epidemiology.
Scratch Test Replacements Sought
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal